The efficacy and safety of addition of bevacizumab to combination chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Single institute experiences in Korea

被引：0
|
作者：
Lee, Y. J.
Kim, Y. M. [1 ]
Mok, J. E. [2 ]
机构：
[1] Asan Med Ctr, Obstet & Gynecol, Seoul, South Korea
[2] Marie Born Womens Hosp, Obstet & Gynecol, Seoul, South Korea
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS-0178
引用
收藏
页码：391 / 391
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF BEVACIZUMAB COMBINATION CHEMOTHERAPY FOR RECURRENT CERVICAL CANCER
    Kusakabe, M.
    Tanikawa, M.
    Oda, K.
    Nagasaka, K.
    Miyamoto, Y.
    Sone, K.
    Mori, M.
    Tsuruga, T.
    Matsumoto, Y.
    Osuga, Y.
    Fujii, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 318 - 318
  • [2] Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer
    Choi, H.
    Kim, B. G.
    Lee, Y. Y.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 275 - 275
  • [3] The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer
    Minion, Lindsey E.
    Tewari, Krishnansu S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (03) : 191 - 198
  • [4] Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
    Ercelep, Ozlem
    Tataroglu, Deniz
    Ozcelik, Melike
    Surmeli, Heves
    Degirmenci, Mustafa
    Inanc, Mevlude
    Aliustaoglu, Mehmet
    Gumus, Mahmut
    [J]. TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 17 (02) : 123 - 127
  • [5] Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer
    Chen, Zhongjie
    Yan, Bo
    Xu, Liming
    Huang, Xin
    Li, Meng
    Wang, Jun
    Zhu, Li
    Yuan, Zhiyong
    Wang, Ping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
    McNamara, Blair
    Chang, Yifan
    Mutlu, Levent
    Harold, Justin
    Santin, Alessandro D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (03) : 227 - 233
  • [7] Efficacy and Safety of Local Radiotherapy Combined with Chemotherapy Bevacizumab in the Treatment of Patients with Advanced and Recurrent Metastatic Cervical Cancer
    Hu, L.
    Fenghu, L.
    Li, J.
    Du, Y.
    Mei, F.
    Tian, X.
    Qin, Y.
    Lu, B.
    Shan, L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E512 - E513
  • [8] A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer
    Friedman, C. F.
    Snyder, A.
    Sharon, E.
    De Meritens, A. Buckley
    Cantrell, L. A.
    Corr, B. R.
    Konner, J.
    Konstantinopoulos, P. A.
    Soldan, K.
    Aghajanian, C. A.
    Zamarin, D.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 17 - 18
  • [9] THE EFFICACY AND SAFETY OF BEVACIZUMAB PLUS CHEMOTHERAPY IN CHINESE PATIENTS WITH RELAPSED AND METASTATIC CERVICAL CANCER
    Liu, Z.
    Chai, Y. L.
    Wang, T.
    Wang, J.
    Shi, F.
    Wang, J. Q.
    Chen, H. W.
    Lu, J. L.
    Zhang, Y. B.
    Gao, Y.
    Wei, L. C.
    Gao, B. Y.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 601 - 601
  • [10] The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study
    Zhu, Jianqing
    Pan, Mei
    Yu, Hao
    Chao, Hongtu
    Chen, Youguo
    Zhao, Hongqin
    Niu, Shuhuai
    Gao, Yuhua
    Wen, Qiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345